ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.14

+1.1%

11:47 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (180)	9/22/2005 12:49:58 PM
From: scaram(o)uche	of 588

"By combining D2 and D3 dopamine partial agonism, M1 muscarinic agonism, and 5-HT2A inverse agonism in a single molecule, ACP-104 uniquely addresses the three most promising target mechanisms for treating psychosis," said Mark R. Brann, Ph.D., ACADIA's President and Chief Scientific Officer. "We believe that ACP-104 represents a new and potential breakthrough approach in schizophrenia therapy." pukin' wimp. coward.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next